This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

TotipotentRX And ThermoGenesis Announce Successful Launch Of Bone Marrow Transplant Program

RANCHO CORDOVA, Calif. and LOS ANGELES and NEW DELHI, India, Aug. 8, 2013 (GLOBE NEWSWIRE) -- TotipotentRX Corporation ("TotiRX"), Fortis Memorial Research Institute ("Fortis") and ThermoGenesis Corp. (Nasdaq:KOOL) today announced the successful launch of their pediatric bone marrow transplant program at the Fortis-TotiRX Centre for Cellular Medicine in New Delhi, India. This week, the new program achieved its first 100-day survival milestone following an allogeneic bone marrow engraftment in a pediatric patient with aplastic anemia using a donor with ABO-incompatible bone marrow having a major blood group mismatch (Patient B+ve, Donor A+ve). The successful transplant was performed using the AXP ® AutoXpress ® Platform ("AXP"), and bone marrow software, a FDA and Drug Controller General of India ("DCGI") approved cell processing platform from ThermoGenesis Corp.

"We are pleased to have achieved this important milestone for our allogeneic bone marrow transplant program," said Dr. Venkatesh Ponemone, Director of Research and Clinical Affairs at TotiRX's Centre for Cellular Medicine operating as Fortis-TotipotentRX. "The AXP Platform, combined with the bone marrow MXP ® MarrowXpress ® ("MXP") protocol, was an integral part of our success with this very challenging inaugural pediatric transplant. In the past, we would have been required to use separation methodologies that reduced the donor red blood cells while unavoidably leading to a significant loss of the stem cells as well. The loss of the precious stem cells increases the risk of engraftment failure in the patient. The adoption of the AXP Platform is another step to improving our probability of a positive clinical outcome in these difficult cases. We will continue to set the processing standard for isolating and concentrating stem cells from bone marrow aspirate and ensuring that all cells transplanted from our lab are delivered with the highest stringency on quality and potency," he continued.

"The successful engraftment in this 10-year old patient demonstrates the quality of our bone marrow transplant program," said Dr. Satya Prakash Yadav, Chief of Pediatric Hematology and Oncology at Fortis Memorial Research Institute where the transplant was completed. "Our clinical expertise, TotiRX's clinical scientists and ThermoGenesis' advanced technology, combined with Fortis' best-in-class facilities make this lifesaving therapy possible. We are proud to lead a world-class team with the expertise to provide cutting edge cellular therapies to children suffering from advanced hematological diseases," he continued.

1 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
SYM TRADE IT LAST %CHG

Markets

DOW 18,266.82 -18.92 -0.10%
S&P 500 2,129.89 -0.93 -0.04%
NASDAQ 5,100.4770 +9.6830 0.19%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs